Navigation Links
Second-most common breast cancer subtype may benefit from personalized treatment approach
Date:2/25/2014

PITTSBURGH, Feb. 26, 2014 The second-most common type of breast cancer is a very different disease than the most common and appears to be a good candidate for a personalized approach to treatment, according to a multidisciplinary team led by University of Pittsburgh Cancer Institute (UPCI) scientists.

Invasive lobular carcinoma, which is characterized by a unique growth pattern in breast tissue that fails to form a lump, has distinct genetic markers that indicate there may be benefits from drug therapies beyond those typically prescribed for the more common invasive ductal carcinoma. The results will be published in the March 1 issue of the journal Cancer Research.

Patients with invasive lobular carcinoma are typically treated through surgical removal of the cancer, followed by chemotherapy or hormone therapy or both, usually with the estrogen-mimicking drug tamoxifen or estrogen-lowering aromatase inhibitors, the same as patients with invasive ductal carcinoma.

"However, recent analyses have shown that a subset of patients with lobular carcinoma receive less benefit from adjuvant tamoxifen than patients with ductal carcinoma," said senior author Steffi Oesterreich, Ph.D., professor at UPCI, a partner with UPMC CancerCenter, and director of education at the Women's Cancer Research Center. "Our study, the largest of its kind, indicates an issue with the estrogen receptors inside lobular carcinoma cells and points to a potential target for drug therapy in future clinical trials, which we are developing."

The UPCI study, funded by the Breast Cancer Research Foundation and the U.S. Department of Defense, included collaborations across multiple disciplines, ranging from biostatistics and biomedical informatics to pathology and human genetics, in order to produce results with the potential for rapid translation into clinical therapies.

"In addition to its potential clinical implications, the study highlights the need for more and bette
'/>"/>

Contact: Allison Hydzik
hydzikam@upmc.edu
412-647-9975
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Finding common ground fosters understanding of climate change
2. Common crop pesticides kill honeybee larvae in the hive
3. Arctic cyclones more common than previously thought
4. How common is aggression in UK dogs?
5. Walking the walk: What sharks, honeybees and humans have in common
6. Study of rodent family tree puts brakes on commonly held understanding of evolution
7. Human error most common cause of birth asphyxia
8. Gene linked to common intellectual disability
9. Model virus structure shows why theres no cure for common cold
10. Common bias known as the endowment effect not present in hunter-gatherer societies
11. OU research team finds a common bioindicator resistant to insecticides
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Second-most common breast cancer subtype may benefit from personalized treatment approach
(Date:7/9/2015)... July 07, 2015 ... addition of the "Biometrics for Banking; Market ... report to their offering. The ... to this growth and the forecast is that ... revenue for companies involved in delivering biometric systems ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced a new Match-in-Sensor™ ... hardware encapsulated fingerprint sensor and matching solution. ... literally off the grid, isolating fingerprint image ... the fingerprint sensor to provide ultimate protection ...
(Date:7/8/2015)... , N.J. and NEW YORK , ... and Guidepoint today announced BD & ... healthcare companies with free access to Guidepoint,s expert network ... start-ups that are developing cutting-edge technologies to improve healthcare ... dedicated Guidepoint research manager, each start-up entrepreneur will be ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... the battle against AIDS and a major development in the ... protein that prevents the virus from entering cells. This protein ... that protects cells from viruses, except the man-made version does ... needed to inhibit AIDS. This discovery was published in the ...
... Reducing Emissions from Deforestation and Forest Degradation ... that aims to financially compensate landowners and stewards ... as promoting forest conservation, sustainable forest management and ... and implemented correctly, REDD+ has the potential to ...
... RIVERSIDE, Calif. What are transposable elements, what role do ... they comprise? Is there an explanation for the genetic diversity ... spotted? What is the genetic basis for this spotted trait? ... a free public lecture at 6 p.m., Thursday, April 14, at ...
Cached Biology News:Intelligent design: Engineered protein fragment blocks the AIDS virus from entering cells 2REDD+, Technical, Socioeconomic and Political Dimensions 2REDD+, Technical, Socioeconomic and Political Dimensions 3Teaching old genomes new tricks 2
(Date:7/30/2015)... July 30, 2015 AACC welcomed thousands ... 2015 AACC Annual Meeting & Clinical Lab Expo ... 26–30. The meeting showcased revolutionary advancements in clinical ... of healthcare providers to diagnose patients quickly and ... treatment. As of Wednesday, July ...
(Date:7/30/2015)... , ... July 30, 2015 , ... The 2015 Market ... study on the current state of the global Propanol market with a focus on ... BASF, Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG ...
(Date:7/30/2015)... Kan. , July 30, 2015   ... a pet therapeutics company focused on the licensing, ... companion animals, today announced that its strategic partner ... a dose confirmation study of AT-016, an adipose-derived ... for the treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)... COPENHAGEN, Denmark , July 30, 2015 /PRNewswire/ ... a biotechnology company that applies its innovative TransCon ... announced positive top-line results from a six-month Phase ... of once-weekly TransCon Growth Hormone in 53 treatment-naïve, ... "We are extremely pleased with the ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... HUYA Bioscience International, a leader in globalizing ... the Shenzhen Polytechnic School of Applied Chemistry and Biotechnology ... in accelerating the development of novel drugs, discovered from ... The agreement provides HUYA with access to and ...
... NephroGenex, Inc., a privately held drug development company, ... the FDA on the design of a new Phase ... nephropathy patients.  This Subpart H program uses a novel ... (SCr), and provides for an accelerated regulatory pathway to ...
... Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a ... extracellular matrix for the diabetes, cancer, dermatology and ... third quarter of 2011 and discussed recent business progress. ... past few months highlight the progress at Halozyme on ...
Cached Biology Technology:HUYA Bioscience International Builds Long-Term Relationship with Shenzhen Polytechnic School of Applied Chemistry and Biotechnology 2HUYA Bioscience International Builds Long-Term Relationship with Shenzhen Polytechnic School of Applied Chemistry and Biotechnology 3NephroGenex Reaches Agreement with the FDA on a Subpart H Phase 3 Program for Pyridorin™ 2Halozyme Therapeutics Reports Third Quarter 2011 Financial Results 2Halozyme Therapeutics Reports Third Quarter 2011 Financial Results 3Halozyme Therapeutics Reports Third Quarter 2011 Financial Results 4Halozyme Therapeutics Reports Third Quarter 2011 Financial Results 5Halozyme Therapeutics Reports Third Quarter 2011 Financial Results 6Halozyme Therapeutics Reports Third Quarter 2011 Financial Results 7
Mouse monoclonal [Ley 37D/G6] to LKB1 ( Abpromise for all tested applications). entrezGeneID: 6794 SwissProtID: Q15831...
... phase reagent for Virus ... & unique water insoluble ... detergents and chaotropes; Engineered ... non-envelop viruses while preserving ...
Integrins Sampler Kit 10g each...
PKC Sampler Kit 10 mu g each...
Biology Products: